Revisiting monoamine oxidase inhibitors.

Published

Journal Article (Review)

Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.

Full Text

Duke Authors

Cited Authors

  • Krishnan, KR

Published Date

  • 2007

Published In

Volume / Issue

  • 68 Suppl 8 /

Start / End Page

  • 35 - 41

PubMed ID

  • 17640156

Pubmed Central ID

  • 17640156

Electronic International Standard Serial Number (EISSN)

  • 1555-2101

Language

  • eng

Conference Location

  • United States